Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Devonian Health GroupDVHGF 61 EV-to-EBITDA is -4.45 as of Aug. 13, 2026. GuruFocus rates DVHGF with a GF Score™ of 61/100 and a GF Value™ of $2.02 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 399 Biotechnology companies, Devonian Health Group ranks worse than 250626.32% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Devonian Health Group's enterprise value is $19.05 Mil.
Devonian Health Group's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 was $-4.28 Mil. Therefore, Devonian Health Group's EV-to-EBITDA for today is -4.45.
The historical rank and industry rank for Devonian Health Group's EV-to-EBITDA or its related term are showing as below:
DVHGF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -165.24 Med: -10.27 Max: 353.77
Current: -3.55
During the past 12 years, the highest EV-to-EBITDA of Devonian Health Group was 353.77. The lowest was -165.24. And the median was -10.27.
DVHGF's EV-to-EBITDA is ranked worse than 100% of 399
companies
in the Biotechnology industry
Industry Median: 13.39
vs DVHGF: -3.55
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Devonian Health Group (OTCPK:DVHGF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Devonian Health Group's PE Ratio (TTM) for today is calculated as:
Devonian Health Group's share price for today is $7.00.
Devonian Health Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.614.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Devonian Health Group EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Devonian Health Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DVHGF vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Devonian Health Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's EV-to-EBITDA falls into.
Devonian Health Group's current Enterprise Value is $19.05 Mil.
Devonian Health Group's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Devonian Health Group (DVHGF) has a EV-to-EBITDA of -4.45 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Devonian Health Group. According to the industry distribution chart, Devonian Health Group ranks #999999 out of 399 companies in the Biotechnology industry.
Is Devonian Health Group's EV-to-EBITDA too high?
Devonian Health Group's current EV-to-EBITDA is -4.45. Based on the distribution chart, Devonian Health Group ranks #999999 out of 399 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Devonian Health Group has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Devonian Health Group ranks #999999 out of 399 companies for EV-to-EBITDA. This places Devonian Health Group in the lower half of its industry. The industry median EV-to-EBITDA is 13.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.39, based on 399 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Devonian Health Group. For the Biotechnology industry, the median EV-to-EBITDA is 13.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Devonian Health Group's current EV-to-EBITDA is -4.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Based on GuruFocus' analysis, Devonian Health Group (DVHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.02, compared to a current price of $7.00 — trading 246.5% above its estimated fair value. The current EV-to-EBITDA is -4.45. Devonian Health Group's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Devonian Health Group (DVHGF), the current EV-to-EBITDA is -4.45 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Devonian Health Group (DVHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued.
The current stock price of $7.00 is trading 246.5% above its estimated GF Value™ of $2.02.
GuruFocus considers Devonian Health Group to be Significantly Overvalued.
Key valuation signals for DVHGF:
EV-to-EBITDA: -4.45
GF Value™: $2.02 vs. price of $7.00 (246.5% above fair value)
No single metric tells the full story. See the DVHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
61GF Score
Get the complete analysis for DVHGF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DVHGF has been successfully added to your 
